These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 24396690)

  • 21. Glucagon-like peptide-1 analogs: Miracle drugs are blooming?
    Gong B; Yao Z; Zhou C; Wang W; Sun L; Han J
    Eur J Med Chem; 2024 Apr; 269():116342. PubMed ID: 38531211
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
    Gallwitz B
    Treat Endocrinol; 2005; 4(6):361-70. PubMed ID: 16318402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.
    Holst JJ
    Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Does glucagon-like peptide-1 receptor agonist therapy add value in the treatment of type 2 diabetes? Focus on exenatide.
    van Genugten RE; van Raalte DH; Diamant M
    Diabetes Res Clin Pract; 2009 Dec; 86 Suppl 1():S26-34. PubMed ID: 20115929
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014 Sep; 143 Suppl 2():2-7. PubMed ID: 25437458
    [TBL] [Abstract][Full Text] [Related]  

  • 26. beta-cell failure in diabetes and preservation by clinical treatment.
    Wajchenberg BL
    Endocr Rev; 2007 Apr; 28(2):187-218. PubMed ID: 17353295
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [New strategy in type 2 diabetes tested in clinical trials. Glucagon-like peptide 1 (GLP-1) affects basic caused of the disease].
    Ahrén B
    Lakartidningen; 2005 Feb 21-27; 102(8):545-9. PubMed ID: 15786905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pleiotropic effects of glucagon-like peptide-1 (GLP-1)-based therapies on vascular complications in diabetes.
    Yamagishi S; Matsui T
    Curr Pharm Des; 2011 Dec; 17(38):4379-85. PubMed ID: 22204436
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
    Gallwitz B
    Minerva Endocrinol; 2006 Jun; 31(2):133-47. PubMed ID: 16682937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Glucagon-like peptide 1 (GLP-1) and metabolic diseases.
    Rotella CM; Pala L; Mannucci E
    J Endocrinol Invest; 2005 Sep; 28(8):746-58. PubMed ID: 16277173
    [TBL] [Abstract][Full Text] [Related]  

  • 31. GLP-1 receptor agonists and DPP-4 inhibitors in the treatment of type 2 diabetes.
    Ahrén B; Schmitz O
    Horm Metab Res; 2004; 36(11-12):867-76. PubMed ID: 15655721
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
    Gallwitz B
    Diabetes Technol Ther; 2005 Aug; 7(4):651-7. PubMed ID: 16120042
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Clinical Impact of GLP-1 Receptor Agonists in Type 2 Diabetes: Focus on the Long-Acting Analogs.
    Rodbard HW
    Diabetes Technol Ther; 2018 Jun; 20(S2):S233-S241. PubMed ID: 29870275
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Incretin-based therapies in type 2 diabetes mellitus.
    Chia CW; Egan JM
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3703-16. PubMed ID: 18628530
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The Role of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes in Asia.
    Lu JM
    Adv Ther; 2019 Apr; 36(4):798-805. PubMed ID: 30859500
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical pharmacology of glucagon-like peptide-1 receptor agonists.
    Sfairopoulos D; Liatis S; Tigas S; Liberopoulos E
    Hormones (Athens); 2018 Sep; 17(3):333-350. PubMed ID: 29949126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes.
    Gautier JF; Fetita S; Sobngwi E; Salaün-Martin C
    Diabetes Metab; 2005 Jun; 31(3 Pt 1):233-42. PubMed ID: 16142014
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incretin-based therapies: can we achieve glycemic control and cardioprotection?
    Angeli FS; Shannon RP
    J Endocrinol; 2014 Apr; 221(1):T17-30. PubMed ID: 23926280
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The physiology of glucagon-like peptide-1 and its role in the pathophysiology of type 2 diabetes mellitus].
    Escalada FJ
    Med Clin (Barc); 2014; 143 Suppl 2():2-7. PubMed ID: 25326836
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mechanisms of the antidiabetic action of subcutaneous glucagon-like peptide-1(7-36)amide in non-insulin dependent diabetes mellitus.
    Schirra J; Leicht P; Hildebrand P; Beglinger C; Arnold R; Göke B; Katschinski M
    J Endocrinol; 1998 Jan; 156(1):177-86. PubMed ID: 9496247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.